134 related articles for article (PubMed ID: 37222312)
1. Relationship between body composition and PBRM1 mutations in clear cell renal cell carcinoma: a propensity score matching analysis.
Demirel E; Dilek O
Rev Assoc Med Bras (1992); 2023; 69(5):e20220415. PubMed ID: 37222312
[TBL] [Abstract][Full Text] [Related]
2. Comments on "Relationship between body composition and PBRM1 mutations in clear cell renal cell carcinoma: a propensity score matching analysis".
Pontes-Silva A; Kovaleva O; Gadzhiakhmedova A; Luchina A; Sinelnikov M; Maslennikov R; Musaeva A; Zharova N; Zharikova T; Zharikov Y
Rev Assoc Med Bras (1992); 2023; 69(9):e20230721. PubMed ID: 37729382
[No Abstract] [Full Text] [Related]
3. Effects on survival of BAP1 and PBRM1 mutations in sporadic clear-cell renal-cell carcinoma: a retrospective analysis with independent validation.
Kapur P; Peña-Llopis S; Christie A; Zhrebker L; Pavía-Jiménez A; Rathmell WK; Xie XJ; Brugarolas J
Lancet Oncol; 2013 Feb; 14(2):159-167. PubMed ID: 23333114
[TBL] [Abstract][Full Text] [Related]
4. Radiogenomics in Clear Cell Renal Cell Carcinoma: Machine Learning-Based High-Dimensional Quantitative CT Texture Analysis in Predicting PBRM1 Mutation Status.
Kocak B; Durmaz ES; Ates E; Ulusan MB
AJR Am J Roentgenol; 2019 Mar; 212(3):W55-W63. PubMed ID: 30601030
[TBL] [Abstract][Full Text] [Related]
5. Commentary on "Effects on survival of BAP1 and PBRM1 mutations in sporadic clear-cell renal-cell carcinoma: a retrospective analysis with independent validation." Kapur P, Peña-Llopis S, Christie A, Zhrebker L, Pavía-Jiménez A, Rathmell WK, Xie XJ, Brugarolas J. Department of Pathology, University of Texas Southwestern Medical Center, Dallas, TX. Lancet Oncol 2013; 14(2):159-67. [Epub 2013 Jan 16]. doi: 10.1016/S1470-2045(12)70584-3.
Boorjian S
Urol Oncol; 2014 Aug; 32(6):934-5. PubMed ID: 25087671
[TBL] [Abstract][Full Text] [Related]
6. A new finding for the obesity paradox? Evaluation of the relationship between muscle and adipose tissue in nuclear grade prediction in patients with clear cell renal cell carcinoma.
Demirel E; Dilek O
Acta Radiol; 2023 Apr; 64(4):1659-1667. PubMed ID: 37023029
[TBL] [Abstract][Full Text] [Related]
7. Genomically annotated risk model for advanced renal-cell carcinoma: a retrospective cohort study.
Voss MH; Reising A; Cheng Y; Patel P; Marker M; Kuo F; Chan TA; Choueiri TK; Hsieh JJ; Hakimi AA; Motzer RJ
Lancet Oncol; 2018 Dec; 19(12):1688-1698. PubMed ID: 30416077
[TBL] [Abstract][Full Text] [Related]
8. Radiogenomics of clear cell renal cell carcinoma: associations between CT imaging features and mutations.
Karlo CA; Di Paolo PL; Chaim J; Hakimi AA; Ostrovnaya I; Russo P; Hricak H; Motzer R; Hsieh JJ; Akin O
Radiology; 2014 Feb; 270(2):464-71. PubMed ID: 24029645
[TBL] [Abstract][Full Text] [Related]
9. Development and validation of a PBRM1-associated immune prognostic model for clear cell renal cell carcinoma.
Chen J; Yao C; Qiao N; Ge Y; Li J; Lin Y; Yao S
Cancer Med; 2021 Oct; 10(19):6590-6609. PubMed ID: 34535962
[TBL] [Abstract][Full Text] [Related]
10. The Impact of PBRM1 Expression as a Prognostic and Predictive Marker in Metastatic Renal Cell Carcinoma.
Kim JY; Lee SH; Moon KC; Kwak C; Kim HH; Keam B; Kim TM; Heo DS
J Urol; 2015 Oct; 194(4):1112-9. PubMed ID: 25997916
[TBL] [Abstract][Full Text] [Related]
11. PBRM1 and VHL expression correlate in human clear cell renal cell carcinoma with differential association with patient's overall survival.
Högner A; Krause H; Jandrig B; Kasim M; Fuller TF; Schostak M; Erbersdobler A; Patzak A; Kilic E
Urol Oncol; 2018 Mar; 36(3):94.e1-94.e14. PubMed ID: 29169846
[TBL] [Abstract][Full Text] [Related]
12. Exploration of
Wang B; Deng Y; Xu Q; Gao J; Shen H; He X; Ding Q; Wang F; Guo H
Clin Radiol; 2023 May; 78(5):e417-e424. PubMed ID: 36805287
[TBL] [Abstract][Full Text] [Related]
13. Clear Cell Renal Cell Carcinoma Subtypes Identified by BAP1 and PBRM1 Expression.
Joseph RW; Kapur P; Serie DJ; Parasramka M; Ho TH; Cheville JC; Frenkel E; Parker AS; Brugarolas J
J Urol; 2016 Jan; 195(1):180-7. PubMed ID: 26300218
[TBL] [Abstract][Full Text] [Related]
14. An integrative genomics approach for identifying novel functional consequences of PBRM1 truncated mutations in clear cell renal cell carcinoma (ccRCC).
Wang Y; Guo X; Bray MJ; Ding Z; Zhao Z
BMC Genomics; 2016 Aug; 17 Suppl 7(Suppl 7):515. PubMed ID: 27556922
[TBL] [Abstract][Full Text] [Related]
15. Expression and Mutation Patterns of PBRM1, BAP1 and SETD2 Mirror Specific Evolutionary Subtypes in Clear Cell Renal Cell Carcinoma.
Bihr S; Ohashi R; Moore AL; Rüschoff JH; Beisel C; Hermanns T; Mischo A; Corrò C; Beyer J; Beerenwinkel N; Moch H; Schraml P
Neoplasia; 2019 Feb; 21(2):247-256. PubMed ID: 30660076
[TBL] [Abstract][Full Text] [Related]
16. The Significance of PARP1 as a biomarker for Predicting the Response to PD-L1 Blockade in Patients with PBRM1-mutated Clear Cell Renal Cell Carcinoma.
Hagiwara M; Fushimi A; Matsumoto K; Oya M
Eur Urol; 2022 Feb; 81(2):145-148. PubMed ID: 34627641
[TBL] [Abstract][Full Text] [Related]
17. Radiogenomics of clear cell renal cell carcinoma: preliminary findings of The Cancer Genome Atlas-Renal Cell Carcinoma (TCGA-RCC) Imaging Research Group.
Shinagare AB; Vikram R; Jaffe C; Akin O; Kirby J; Huang E; Freymann J; Sainani NI; Sadow CA; Bathala TK; Rubin DL; Oto A; Heller MT; Surabhi VR; Katabathina V; Silverman SG
Abdom Imaging; 2015 Aug; 40(6):1684-92. PubMed ID: 25753955
[TBL] [Abstract][Full Text] [Related]
18. Prognostic impact of concomitant loss of PBRM1 and BAP1 protein expression in early stages of clear cell renal cell carcinoma.
da Costa WH; da Cunha IW; Fares AF; Bezerra SM; Shultz L; Clavijo DA; da Silva DV; Netto GJ; Guimaraes GC; Cassio Zequi S
Urol Oncol; 2018 May; 36(5):243.e1-243.e8. PubMed ID: 29426696
[TBL] [Abstract][Full Text] [Related]
19. Decreased PBRM1 expression predicts unfavorable prognosis in patients with clear cell renal cell carcinoma.
Nam SJ; Lee C; Park JH; Moon KC
Urol Oncol; 2015 Aug; 33(8):340.e9-16. PubMed ID: 26003625
[TBL] [Abstract][Full Text] [Related]
20. BAP1, PBRM1 and SETD2 in clear-cell renal cell carcinoma: molecular diagnostics and possible targets for personalized therapies.
Piva F; Santoni M; Matrana MR; Satti S; Giulietti M; Occhipinti G; Massari F; Cheng L; Lopez-Beltran A; Scarpelli M; Principato G; Cascinu S; Montironi R
Expert Rev Mol Diagn; 2015; 15(9):1201-10. PubMed ID: 26166446
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]